Indirect comparison of abiraterone acetate and docetaxel for treatment of metastatic "hormone-sensitive" prostate cancer

被引：0
|
作者：
Feyerabend, S. [1 ]
Saad, F. [2 ]
Li, T. [3 ]
Ito, T. [4 ]
Diels, J. [5 ]
Van Sanden, S. [5 ]
De Porre, P. [6 ]
Roiz, J. [7 ]
Abogunrin, S. [8 ]
Fizazi, K. [9 ]
机构：
[1] Studienpraxis Urol, Urol Oncol, Nurtingen, Germany
[2] CRCHUM, Ctr Hosp Univ Montreal, Surg, Montreal, PQ, Canada
[3] Janssen Global Serv, Global Market Access Oncol, Raritan, NJ USA
[4] Janssen, Hlth Econ & Market Access EMEA, High Wycombe, Bucks, England
[5] Janssen, Hlth Econ & Market Access EMEA, Beerse, Belgium
[6] Janssen Res & Dev BE, Clin Oncol, Beerse, Belgium
[7] Modeling & Simulat, London, England
[8] Evidera, Outcomes Res, London, England
[9] Univ Paris Sud, Inst Gustave Roussy, Canc Med, Villejuif, France
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
803P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer
    Tsaur, Igor
    Heidegger, Isabel
    Bektic, Jasmin
    Kafka, Mona
    van den Bergh, Roderick C. N.
    Hunting, Jarmo C. B.
    Thomas, Anita
    Brandt, Maximilian P.
    Hoefner, Thomas
    Debedde, Eliott
    Thibault, Constance
    Ermacora, Paola
    Zattoni, Fabio
    Foti, Silvia
    Kretschmer, Alexander
    Ploussard, Guillaume
    Rodler, Severin
    von Amsberg, Gunhild
    Tilki, Derya
    Surcel, Christian
    Rosenzweig, Barak
    Gadot, Moran
    Gandaglia, Giorgio
    Dotzauer, Robert
    [J]. CANCER MEDICINE, 2021, 10 (18): : 6354 - 6364
  • [2] Abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer in China: an indirect treatment comparison and cost analysis
    Xin Hu
    Shuli Qu
    Xingxing Yao
    Chaoyun Li
    Yanjun Liu
    Jianye Wang
    [J]. Cost Effectiveness and Resource Allocation, 17
  • [3] Abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer in China: an indirect treatment comparison and cost analysis
    Hu, Xin
    Qu, Shull
    Yao, Xingxing
    Li, Chaoyun
    Liu, Yanjun
    Wang, Jianye
    [J]. COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2019, 17 (01)
  • [4] Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
    Talwar, Harkirat Singh
    [J]. INDIAN JOURNAL OF UROLOGY, 2021, 37 (03) : 288 - 290
  • [5] Docetaxel for hormone-sensitive metastatic prostate cancer
    Baker, Holly
    [J]. LANCET ONCOLOGY, 2015, 16 (09): : E432 - E432
  • [6] Abiraterone vs. docetaxel for metastatic hormone-sensitive prostate cancer: A microsimulation model
    Hird, Amanda E.
    Magee, Diana E.
    Cheung, Douglas C.
    Matta, Rano
    Kulkarni, Girish S.
    Nam, Robert K.
    [J]. CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2020, 14 (09): : E418 - E427
  • [7] Abiraterone acetate in combination with prednisone in the treatment of metastatic hormone-sensitive prostate cancer: clinical evidence and experience
    Purshouse, Karin
    Protheroe, Andrew S.
    [J]. THERAPEUTIC ADVANCES IN UROLOGY, 2019, 11
  • [8] Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy
    Yanagiswawa, T.
    Hata, K.
    Narita, S.
    Hatakeyama, S.
    Mori, K.
    Yata, Y.
    Sano, T.
    Otsuka, T.
    Hara, S.
    Miyajima, K.
    Enei, Y.
    Fukuokaya, W.
    Nakazono, M.
    Matsukawa, A.
    Miki, J.
    Habuchi, T.
    Ohyama, C.
    Shariat, S. F.
    Kimura, T.
    [J]. EUROPEAN UROLOGY, 2023, 83
  • [9] Docetaxel Treatment for Metastatic Hormone-sensitive Prostate Cancer in Daily Practice
    de Groot, Ietsen
    Brinkman, Ithamar
    Luijendijk-de Bruin, Daphne
    Poort, Sharon
    van Rooijen, Johan M.
    [J]. EUROPEAN UROLOGY OPEN SCIENCE, 2021, 33 : 48 - 55
  • [10] Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy
    Yanagisawa, Takafumi
    Hata, Kenichi
    Narita, Shintaro
    Hatakeyama, Shingo
    Mori, Keiichiro
    Yata, Yuji
    Sano, Takayuki
    Otsuka, Takashi
    Hara, Shuhei
    Miyajima, Keiichiro
    Enei, Yuki
    Fukuokaya, Wataru
    Nakazono, Minoru
    Matsukawa, Akihiro
    Miki, Jun
    Habuchi, Tomonori
    Ohyama, Chikara
    Shariat, Shahrokh F.
    Kimura, Takahiro
    [J]. PROSTATE, 2023, 83 (06): : 563 - 571
12345